The role of data in phar­ma­ceut­ical industry and clin­ical trials


Not all patients who are diagnosed with Autoantibodies in Breast Cancer Detection (ABCD) may respond to treat­ment and drugs avail­able today. Their last altern­at­ive is to explore drugs and treat­ment in clin­ical trials. Unfortunately, avail­ab­il­ity of such inform­a­tion in a coher­ent simple to under­stand plat­form is a luxury. Clinical trials are done when all avail­able treat­ments have proven unsuc­cess­ful yet the process of enrolling in a clin­ical trial can be expens­ive, time consum­ing and complic­ated for the patients. High cost of research and devel­op­ment in drug design results in higher drug prices and higher insur­ance premi­ums. The US govern­ment estim­ates that as at May 2018, only 3% of cancer patients are enrolled for clin­ical trials. How can clin­ical trials be made less expens­ive, effi­cient and more access­ible to patients?

Datasets used

One of the reas­ons why clin­ical trials fail is due to data collec­tion process. A first step is access to curated data­base of clin­ical trials where patients can directly search based on categor­ies and loca­tion. In addi­tion, anonymised patient inform­a­tion and drug analysis report can be viewed on the data market­place. Availability of this inform­a­tion rather than oral recom­mend­a­tion from health person­nel will increase the percent­age of patients involved in such clin­ical trials. The process even becomes more effi­cient when the Research team have digital copies (not pdf or fax) of patient medical records and previ­ous treat­ment reports. The Advaneo data market­place has been developed to address this.

Advaneo Data Marketplace

Among the numer­ous features of the data market­place of relev­ance to the health­care sector espe­cially clin­ical trials is ensur­ing secur­ity and privacy while facil­it­at­ing seam­less exchange of data to selec­ted medical insti­tu­tions. The Advaneo data market­place offers:

Security and Privacy

No data­set will be stored on the market­place rather, veri­fied data endpoints to where such inform­a­tion can be obtained is provided in addi­tion to a stand­ard­ised descrip­tion of the data­set (metadata). The data provider (patient/hospital) main­tains the data­set with 100% data governance.

Broker Service

Supplementary inform­a­tion such as diet­ary habits, activ­ity and sleep cycle can be inde­pend­ently gathered by the patient using a vari­ety of smart­phone apps and wear­ables. This data which belongs to the patient can be shared freely or traded by the patient. Our broker service ensures this is done with no complic­ated over­head on the data provider. Such data­sets will prevent depend­ence on subject­ive response during clin­ical trials.

Closed User Groups

The progress and final results of clin­ical trials can become trade secrets that should kept private to parties involved in the process. The data market­place provides the option to create closed user groups. The exist­ence of such groups and members will remain incog­nito. More import­antly the metadata is only visible by the members of the group and the data­set are exchange directly between pairs.


The search for appro­pri­ate drugs to treat cancer by using clin­ical trial analysis is currently a long expens­ive process. Collation and avail­ab­il­ity of high qual­ity data­sets will be a signi­fic­ant step towards trans­form­ing the process. In addi­tion, the possib­il­it­ies become endless when machine learn­ing tools are applied to these data­sets for patient to clin­ical trial match­ing, early anom­aly diagnosis and data driven drug design process. The avail­ab­il­ity of data will also aid machine learn­ing applic­a­tions in preven­tion and early diagnosis of health pandem­ics. In fact, deep learn­ing applic­a­tions will contrib­ute 3 billion dollars to the health­care sector by 2025. This will lead to signi­fic­ant reduc­tion in cost of health­care while creat­ing new busi­ness oppor­tun­it­ies in the health­care sector.